480 Biomedical Inc.

Lyra Therapeutics, Inc.

Medtronic Vascular, Inc.

Arsenal Medical, Inc.

Biomedical, Inc.

Danny Concagh

Changcheng You

Quynh P Pham

Gregory T Zugates

Maria Palasis

Upma Sharma

Lee A Core

Kicherl Ho

Jeffrey Groom, Ii

Nikhita Mansukhani

Craig Wiltsey

Kate Rielly

Greg Zugates

Chang Cheng You

Jeffrey Groom

Rany Busold

This disclosure describes various sinus scaffolds having fiber-based and non-fiber based designs, materials, devices, kits and methods that may be used to treat chronic sinusitis. These designs vary in form, dimension, and delivery location (i.e., maxillary, frontal, ethmoidal, sphenoidal sinuses, and middle meatus). In addition, therapeutic agent(s) may optionally be included within the scaffolds for local delivery over a brief or extended period of time.

Implantable scaffolds for treatment methods of sinusitus

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. The present disclosure describes various sinus scaffolds having fiber-based and non-fiber-based designs. These designs vary in form, dimension, and delivery location. In addition, therapeutic agent(s) may optionally be included within the scaffolds for local delivery over a brief or extended period of time. Therefore, these scaffolds may be used to improve sinus patency, for example, in surgically modified sinus spaces or in sinus spaces that have not previously undergone surgical modification. Moreover, these scaffolds may be used to deliver local therapeutic agent(s) to such sinus spaces, including, for instance, as part of a treatment program that is an alternative to sinus surgery (e.g., FESS) or in other instances as part of a postoperative care of FESS in some embodiments.

Implantable scaffolds for treatment of sinusitis

The present disclosure pertains to crosslinkable compositions and systems as well as methods for forming crosslinked compositions in situ, including the use of the same for controlling the movement of bodily fluid within a patient, among many other uses.

Crosslinkable polymer compositions

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. More specifically, a drug-eluting scaffold is implanted in the middle meatus to treat chronic sinusitis for weeks to months.

Implantable scaffolds for treatment of sinusitis and method of reducing inflammation

This disclosure describes various sinus scaffolds having fiber-based and non-fiber based designs, materials, devices, kits and methods that may be used to treat chronic sinusitis. These designs vary in form, dimension, and delivery location (i.e. maxillary, frontal, ethmoidal, sphenoidal sinuses, and middle meatus). In addition therapeutic agent(s) may optionally be included within the scaffolds for local delivery over a brief or extended period of time.

Implantable scaffolds for treatment of sinusitus

Disclosed are self-expanding medical implants for placement within a lumen of a patient. The implants comprise a woven or non-woven structure having a substantially tubular configuration, and are designed to be low-profile such that they are deliverable with a small diameter catheter. The implants have a high recoverability and desired mechanical properties.

Drug eluting medical implant

Drug-eluting medical implants

This disclosure describes, inter alia, materials, devices, kits and methods for the treatment of chronic sinusitis. Disclosed are medical scaffolds configured for placement within a sinus of a patient, methods of making the implants and methods of treatment. The scaffolds comprise a woven or non-woven structure having a substantially tubular configuration, a conformal coating over the tubular scaffold and optionally, a drug coating.

Implantable scaffolds and methods for treatment of sinusitis

This disclosure describes, inter alia, materials, devices, kits and methods that may be used to treat chronic sinusitis. Disclosed are biodegradable medical scaffolds for placement within sinus cavity of a patient, methods of making the implants and methods of treatment. The scaffolds comprise a structure having a substantially tubular configuration and a therapeutic-agent-containing layer.

Disclosed are medical implants for placement within a lumen of a patient. The implants comprise a polymer and drug-coated metal structure having a tubular configuration and designed to deliver the drug to target tissue at tailored linear drug elution rate.

Growing community of inventors

Medfield, MA, United States of America

Danny Concagh